Understanding the Oral Mucosal Absorption and Resulting Clinical Pharmacokinetics of Asenapine

被引:50
作者
Bartlett, Jeremy A. [1 ]
Maarschalk, Kees van der Voort [2 ,3 ]
机构
[1] Pfizer Global Res & Dev, Worldwide Pharmaceut Sci, Pharmaceut Dev, Groton, CT 06340 USA
[2] Purac Biochem, Competence Ctr Proc Technol, Gorinchem, Netherlands
[3] Univ Groningen, Dept Pharmaceut Technol & Biopharm, NL-9713 AV Groningen, Netherlands
关键词
asenapine; exposure; oral mucosal absorption; T-max; SUBLINGUALLY ADMINISTERED ASENAPINE; HUMAN BUCCAL ABSORPTION; HEALTHY MALE-VOLUNTEERS; PHYSICOCHEMICAL PROPERTIES; BASIC DRUGS; KINETICS; SINGLE; BIOAVAILABILITY; PROPRANOLOL; MODEL;
D O I
10.1208/s12249-012-9839-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Absorption of drugs from the oral cavity into the mucosal tissues is typically a fast event. Dissolved drugs partition into the mucosal membranes and within minutes will reach equilibrium with drug in solution in the oral cavity. However, this does not always equate to rapid drug appearance in the systemic circulation. This has been attributed to slow partitioning out of the mucosal tissues and into the systemic circulation. Based on information from literature, physicochemical properties of asenapine, and clinical data, we conclude that for sublingually administered asenapine, the exposure is primarily a function of rapid partitioning into the mucosal membranes. This is followed by slow partitioning out of the mucosal tissues and into the systemic circulation, leading to a T-max value of about 1 h. The bioavailability of asenapine at doses below the saturation solubility in the mouth does not change and is controlled primarily by mass transport equilibrium. At doses above the saturation solubility, the bioavailability becomes more dependent not only on the distribution equilibrium but also on contact time in the mouth because additional variables (e. g. dissolution rate of the drug) need to be accounted for. These explanations are consistent with oral cavity absorption models from the literature and can be used to accurately describe the clinical data for asenapine.
引用
收藏
页码:1110 / 1115
页数:6
相关论文
共 36 条
[11]  
Hulskotte E, 2009, CLIN PHARMACOL THER, V85, pS86
[12]  
Jensen KM, 1997, ARZNEIMITTEL-FORSCH, V47, P716
[13]  
KATES RE, 1977, J MED, V8, P393
[14]   Clinical pharmacokinetics of vasodilators - Part II [J].
Kirsten, R ;
Nelson, K ;
Kirsten, D ;
Heintz, B .
CLINICAL PHARMACOKINETICS, 1998, 35 (01) :9-36
[15]   TRIAZOLAM PHARMACOKINETICS AFTER INTRAVENOUS, ORAL, AND SUBLINGUAL ADMINISTRATION [J].
KROBOTH, PD ;
MCAULEY, JW ;
KROBOTH, FJ ;
BERTZ, RJ ;
SMITH, RB .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1995, 15 (04) :259-262
[16]   THE VOLUME OF SALIVA IN THE MOUTH BEFORE AND AFTER SWALLOWING [J].
LAGERLOF, F ;
DAWES, C .
JOURNAL OF DENTAL RESEARCH, 1984, 63 (05) :618-621
[17]   Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naive healthy male volunteers under a naltrexone block [J].
McAleer, SD ;
Mills, RJ ;
Polack, T ;
Hussain, T ;
Rolan, PE ;
Gibbs, AD ;
Mullins, FGP ;
Hussein, Z .
DRUG AND ALCOHOL DEPENDENCE, 2003, 72 (01) :75-83
[18]   CLINICAL PHARMACOKINETICS OF DRUGS ADMINISTERED BUCCALLY AND SUBLINGUALLY [J].
MOTWANI, JG ;
LIPWORTH, BJ .
CLINICAL PHARMACOKINETICS, 1991, 21 (02) :83-94
[19]   ABSORPTION OF DRUGS FROM THE HUMAN ORAL CAVITY [J].
RATHBONE, MJ ;
HADGRAFT, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1991, 74 (01) :9-24
[20]   HUMAN BUCCAL ABSORPTION .1. A METHOD FOR ESTIMATING THE TRANSFER KINETICS OF DRUGS ACROSS THE HUMAN BUCCAL MEMBRANE [J].
RATHBONE, MJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1991, 69 (02) :103-108